Strong Revenue Growth
Fiscal Q2 revenue of $1.164B, a 19% year-over-year increase and fifth consecutive quarter of sequential revenue growth; Q3 revenue guidance of $1.2B–$1.25B (midpoint ~20% YoY and ~5% sequential growth).
Record Program Wins and Expanding Funnel
Record $355M in annualized new manufacturing program wins across 30 programs in Q2; funnel of qualified manufacturing opportunities expanded 11% sequentially to $4.0B, with aerospace & defense and industrial funnels up >45% YoY.
Sector Momentum — Industrial and Aerospace & Defense
Industrial revenue up 12% sequentially in Q2 with record sector wins of $195M (including data center power and robotics); Aerospace & Defense revenue rose 19% sequentially with $44M in Q2 wins and expected sector growth well into double digits for FY2026.
Healthcare/Life Sciences Wins and Outlook
Healthcare/Life Sciences had $116M in Q2 wins (point-of-care ultrasound, robotic surgical platforms); Q2 revenue essentially flat sequentially (+1%) with outlook for resumed sequential growth into Q4 and FY2026 growth above the company 9%–12% goal.
Profitability Above Guidance
Non-GAAP operating margin of 6% in Q2 (at top end of guidance) and non-GAAP diluted EPS of $2.05 exceeded guidance; gross margin at 10.2% (top end of guidance).
Improved Working Capital & Cash Position
Q2 cash from operations $28.5M, capital expenditures $12.5M, free cash flow $16M (better than forecast); ended quarter in a net cash position, repurchased ~109,000 shares for $20.6M with ~$42M remaining authorization; cash cycle improved to 64 days (down 5 days sequentially).
Strong Return on Invested Capital
Q2 ROIC of 13.8%, 480 basis points above the company's weighted average cost of capital, demonstrating strong capital efficiency despite increased invested capital to support growth.
Confident FY2026 Guidance
Company raised FY2026 outlook to expect mid-teens or greater revenue growth and a 6%+ non-GAAP operating margin, with FY2026 free cash flow guidance of $50M–$75M and CapEx of $100M–$120M.